These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9418156)

  • 1. The dynamics of human immunodeficiency virus type 1 transmission among injecting drug users.
    Nicolosi A; Villa M; Leite ML
    J Biol Regul Homeost Agents; 1997; 11(1-2):20-6. PubMed ID: 9418156
    [No Abstract]   [Full Text] [Related]  

  • 2. Human immunodeficiency virus and the substance abuser: public policy considerations.
    Ruiz P; Fernandez F
    Tex Med; 1994 May; 90(5):64-7. PubMed ID: 8029770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
    Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpreting the relation between injection drug use and harm: a cautionary note.
    Anderson JF
    CMAJ; 2000 Jun; 162(12):1695-6. PubMed ID: 10870501
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prevalence of human immunodeficiency virus infection and behaviors associated with its transmission among parenteral drug users selected on the street].
    Rodés A; Vall M; Casabona J; Nuez M; Rabella N; Mitrani L
    Med Clin (Barc); 1998 Oct; 111(10):372-7. PubMed ID: 9833239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-associated behaviors among injecting-drug users--23 Cities, United States, May 2005-February 2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Apr; 58(13):329-32. PubMed ID: 19357632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment.
    Platt L; Bobrova N; Rhodes T; Uusküla A; Parry JV; Rüütel K; Talu A; Abel K; Rajaleid K; Judd A
    AIDS; 2006 Oct; 20(16):2120-3. PubMed ID: 17053361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prevalence of human immunodeficiency virus infection and the risk behaviors in the heroin addicts of Barcelona, Madrid and Seville: an example of the advantages of centering studies on addicts and not just on intravenous users].
    de la Fuente L; Bravo MJ; Lew C; Barrio G; Soriano V; Royuela L
    Med Clin (Barc); 1999 Nov; 113(17):646-51. PubMed ID: 10618778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in human immunodeficiency virus infection among drug users in a detoxification unit.
    Muga R; Sanvisens A; Egea JM; Tor J; Rey-Joly C
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S404-9. PubMed ID: 14648455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Western Europe's response to HIV divided by regions.
    AIDS Alert; 2002 May; 17(5):59-61. PubMed ID: 12030216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring effectiveness of needle and syringe exchange programmes for prevention of HIV among injecting drug users.
    Amundsen EJ
    Addiction; 2006 Jul; 101(7):911-2. PubMed ID: 16771880
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV and HCV infection among injecting drug users.
    Hagan H; Des Jarlais DC
    Mt Sinai J Med; 2000; 67(5-6):423-8. PubMed ID: 11064493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV among drug injectors: the epidemic and the response.
    Friedman SR; Des Jarlais DC
    AIDS Care; 1991; 3(3):239-50. PubMed ID: 1932186
    [No Abstract]   [Full Text] [Related]  

  • 15. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
    Devi KhS; Brajachand N; Singh HL; Singh YM
    J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City.
    Des Jarlais DC; Arasteh K; Perlis T; Hagan H; Abdul-Quader A; Heckathorn DD; McKnight C; Bramson H; Nemeth C; Torian LV; Friedman SR
    AIDS; 2007 Jan; 21(2):231-5. PubMed ID: 17197815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users.
    Kretzschmar M; Wiessing L
    AIDS; 2008 Aug; 22(13):1527-37. PubMed ID: 18670211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study.
    Sutton AJ; Hope VD; Mathei C; Mravcik V; Sebakova H; Vallejo F; Suligoi B; Brugal MT; Ncube F; Wiessing L; Kretzschmar M
    J Viral Hepat; 2008 Nov; 15(11):809-16. PubMed ID: 18761605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV transmission among drug users in Larkana, Pakistan.
    ur Rehman N; Emmanuel F; Akhtar S
    Trop Doct; 2007 Jan; 37(1):58-9. PubMed ID: 17326898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.
    Mohsen AH; Murad S; Easterbrook PJ
    HIV Med; 2005 May; 6(3):206-15. PubMed ID: 15876288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.